Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOS161721 in Systemic Lupus Erythematosus
NCT03371251Phase 2Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Nov 2020
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of avizakimab in systemic lupus erythematosus (SLE) (4 arms), sponsored by Boston Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events at Day 270 and SLE Responder Index 4 Response at Day 210. Started Jan 2018; status: completed.
02
Drugs
avizakimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03371251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371251.